Sorrento's R&D tau tsom mus rau kev tsav tsheb tshiab hauv COVID-19, kev kho mob qog noj ntshav, kev tswj mob tag nrho thiab kab mob autoimmune.

Cov Txheej Txheem Tseem Ceeb	Kev qhia	Peb muaj	Theem I	Qis II	Phase III/Pivotal	Tso Cai FDA
Cov kev pab cuam COVID-19
COVISTIX™ (kev kuaj mob) Rapid Antigen Test 0%* Kev Tso Cai Siv Thaum Muaj Xwm Ceev (EUA) hauv Mexico (COFEPRIS), Brazil (ANVISA), thiab CE Marked hauv Tebchaws Europe COVIMARK™ (kev kuaj mob) Rapid Antigen Test 0%* Daim ntawv thov xa hauv Asmeskas thiab Canada rau Kev Tso Cai Siv Thaum Muaj Xwm Ceev (EUA) VIREX (kev kuaj mob) Hauv Tsev Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COV-MSC) ARDS vim yog COVID-19 hauv ICU Cov Neeg Mob 82%* Pivotal Trial hauv Brazil                           OVYDSO (Olgotrelvir) Anti-kis (Qhov ncauj ntsiav tshuaj) 40%* Omicron mRNA tshuaj tiv thaiv Tshuaj Tiv Thaiv 20%*
Cov Txheej Txheem Tseem Ceeb	Kev qhia	Peb muaj	Theem I	Qis II	Phase III/Pivotal	Tso Cai FDA
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) prostate 20%* PD-L1 (Socazolimab) * SCLC 82%* * Hauv kev koom tes nrog Lee's Pharm hauv Suav teb PD-L1 (STI-3031) ncauj tsev menyuam Cancer 82%* ** Hauv Asmeskas thiab koom tes nrog ImmuneOncia hauv Kaus Lim Kauslim CD47 Cov qog nqaij hlav 40%* CD38 DAR-T Ntau yam mob Myeloma 40%* CD38 ADC Amyloidosis, Ntau Myeloma, T-ALL, thiab esophageal 40%* TROP2 ADC* Cov qog nqaij hlav 40%* Seprehvec™ oncolytic virus Cov qog nqaij hlav; CNS qog 40%* BCMA ADC Liquid Tumors 20%* Bevacizumab-ADNAB™ Endometrial Cancer 40%* Hauv kev koom tes nrog Mayo Clinic Bevacizumab-ADNAB™ Cancer ntawm pojniam 40%* Hauv kev koom tes nrog Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Hauv kev koom tes nrog Mayo Clinic Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Cov Txheej Txheem Tseem Ceeb	Kev qhia	Peb muaj	Theem I	Qis II	Phase III/Pivotal	Tso Cai FDA
mob
ZTlido® 1.8% Postherpetic Neuralgia - PHN 99.8%* Gloperba® Kev kho mob ntawm Gout (Qhov ncauj) 99.8%* SEMDEXA (SP-102) Lumbar Radicular / Sciatica Mob 82%* SP-103 (Lidocaine Topical System 5.4%) Mob Mob Siab 60.2%* SP-104 (Delayed Burst Low Dose Naltrexone) fibromyalgia 20%* RTX (resiniferatoxin) Kev txhaj tshuaj Epidural Intractable Mob nyob rau hauv Advanced Cancer 60.3%* Orphan npe RTX (resiniferatoxin) Intra-articular txoj kev Nruab nrab mus rau Hneev OA Mob 60.2%*
Cov Txheej Txheem Tseem Ceeb	Kev qhia	Peb muaj	Theem I	Qis II	Phase III/Pivotal	Tso Cai FDA
Lymphatic Drug Delivery
Sofusa® tiv thaiv TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* Hauv kev koom tes nrog Mayo Clinic

Cov kev pab cuam COVID-19
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia)	Sij hawm
COVISTIX™ (kev kuaj mob) FDA EUA COVIMARK™ (kev kuaj mob) FDA EUA VIREX (kev kuaj mob) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COV-MSC) Ph III Olgotrelvir (OVYDSO) Ph II Omicron mRNA tshuaj tiv thaiv Peb muaj

immunotherapy
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia)	Sij hawm
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Peb muaj PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Cov qog nqaij hlav) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Ntau Myeloma, T-ALL, thiab esophageal) Ph I TROP2 ADC* (Cov qog nqaij hlav) Ph I Seprehvec™ oncolytic virus (Cov qog nqaij hlav; CNS qog) PH I BCMA ADC (Liquid Tumors) Peb muaj Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

mob
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia)	Sij hawm
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Tso Cai FDA Gloperba® 1.8% Kev kho mob ntawm Gout (Qhov ncauj) Tso Cai FDA SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Delayed Burst Low Dose Naltrexone) Peb muaj RTX (resiniferatoxin) Kev txhaj tshuaj Epidural Ph II RTX (resiniferatoxin) Intra-articular txoj kev Ph II

Lymphatic xa khoom
Cov Txheej Txheem Tseem Ceeb (Kev taw qhia)	Qis II
Sofusa® tiv thaiv TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I